Argon Medical to launch Cleaner15 technology for mechanical thrombectomy procedures

Furthering its commitment to advancing the treatment of patients diagnosed with ESRD (End Stage Renal Disease), Argon Medical Devices, Inc. takes another leap forward with the launch of the Cleaner15™ Rotational Thrombectomy System.  The addition of Cleaner15™ to Argon Medical's product portfolio provides physicians with another weapon in their arsenal to safely and effectively restore patency in occluded arteriovenous fistulae and synthetic grafts.

"We are excited to introduce this leading-edge addition to the Cleaner line of devices," commented George A. Leondis , President of Argon. "The introduction of Cleaner15™ illustrates Argon's commitment to providing best-in-class technologies that enable clinicians to improve outcomes for patients undergoing mechanical thrombectomy procedures."

The Cleaner15™ Rotational Thrombectomy System utilizes a 15mm single, sinusoidal wire that allows for safe and effective thrombus removal. The 0.044 wire combined with the increase in torque provides the physician with the power needed for difficult declot cases resulting in reduced procedure time, along with enhanced steerability in tight stenoses and aneurysms. (Cleaner15™ Rotational Thrombectomy System is designed and manufactured by Rex Medical, L.P., Conshohocken, PA).

"The Cleaner15™ technology provides efficiency and robust power in challenging thrombectomy cases.  The radial force of the sinusoidal wire engages thrombus and has the ability to expand to 15mm allowing for maceration of thrombus effectively, while maintaining procedural safety. I feel very comfortable using the device in all applications including stents and venous valves without risk of binding," stated Dr. Mark Goldberg , MD, Medical Director of the Center for Dialysis Access, Oakwood, OH.

Argon Medical will be exhibiting at the 25^th Annual International Society of Endovascular Therapy (ISET) Scientific Meeting to be held in Miami, FL from January 19^th thru the 23rd at the Fontainebleau Miami Beach.

Nearly 600,000 patients currently undergo treatment in the U.S. for End-Stage Renal Disease (ESRD).  In addition, over 300,000 procedures are being performed annually in the U.S. to repair and clear thrombosed hemodialysis access grafts and fistulae. It is estimated that the dialysis patient population will continue to grow at a rate exceeding 6% annually.